VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LEGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LEGNLegend Biotech Corporation
$16.11$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLEGNCash Flow

Legend Biotech Corporation (LEGN) Cash Flow Statement

9Y historyFree accessUpdated daily

Operating cash flow was -$35.9M in 2026Q3 against $51.7M of net income, with working capital changes of -$94.2M suggesting receivable or inventory dynamics are a primary driver of persistent cash burn.

Income StatementBalance SheetCash FlowRatios

LEGN Cash Flow Statement

Annual statement

LEGN Cash Flow Statement

Legend Biotech Corporation (LEGN) cash flow statement — 9-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Cash from Operations-247.8M-100.47M-144.03M-393.28M-201.28M-198.47M-223M-83.06M307.68M-2.38M
Operating CF Margin %--9.76%-22.96%-137.92%-172.03%-288.36%-297.34%-134.41%626.22%-10.07%
Operating CF Growth %-295.88%30.25%63.38%-95.39%-1.42%11%-168.47%-127%13049.58%-
Net Income-215K-297.58M-158.13M-520.12M-445.72M-407.2M-308.29M-130.37M-1.62M9.37M
Depreciation & Amortization50.27M28.9M23.36M20.45M18.39M13.92M9.93M5.26M1.68M217K
Stock-Based Compensation7.7M068.94M47.68M34.34M20.16M4.76M1.27M704K0
Deferred Taxes0000000-7.35M-5.66M0
Other Non-Cash Items-1.44M261.57M-98.24M130.06M10.68M12.82M93.83M-4.36M-6.13M228.87M
Working Capital Changes-301.51M-93.35M20.04M-71.34M181.03M161.83M-23.24M52.48M318.71M-16.5M
Change in Receivables-125.44M-132.85M93.75M-98.98M50.32M24.59M-45M-3.77M207.61M-228.06M
Change in Inventory-7.97M-4.51M-17.21M-12.71M-13.89M51K-643K-22K-1.12M-6K
Change in Payables-26.31M44.52M14.06M-50.2M72.45M1.8M-4.35M2.01M3.24M4.17M
Cash from Investing226.82M711.48M-850.54M92.79M-77.09M-194.98M-24.17M-58.65M-102.26M-827K
Capital Expenditures-52.49M-67.58M-14.11M-20.08M-20.93M-42.2M-26.25M-39.17M-21.02M-887K
CapEx % of Revenue3.86%6.57%2.25%7.04%17.89%61.31%35.01%63.38%42.78%3.76%
Acquisitions0000000-460K20K60K
Investments----------
Other Investing-135.1M0-54.34M-100.52M-16.05M-4.91M-23.52M50.52M-75.23M55K
Cash from Financing115.15M-300.79K5.7M791.49M377.98M626.66M618.88M14.67M2.5M3.32M
Debt Issued (Net)-50.6M0-4.02M-3.75M-2.6M-1.42M-2.6M-5.06M-219K-32K
Equity Issued (Net)213.36M3.31M00377.64M623.44M622.53M000
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing-47.61M-3.61M9.72M795.25M2.93M4.64M-1.05M19.72M2.72M3.35M
Net Change in Cash181.76M615.09M-990.96M491.68M97.09M233.25M372.32M-126.8M208.05M128K
Free Cash Flow-320.88M-168.04M-158.14M-416M-223.56M-243.87M-253.29M-122.23M286.66M-3.26M
FCF Margin %-23.62%-16.33%-25.21%-145.89%-191.07%-354.33%-337.72%-197.79%583.44%-13.83%
FCF Growth %-70.06%-6.26%61.99%-86.08%8.33%3.72%-107.21%-142.64%8885.2%-
FCF per Share-1.66-0.91-0.86-2.36-1.41-1.73-2.14-0.932.86-0.02
FCF Conversion (FCF/Net Income)1492.45x0.34x0.81x0.76x0.45x0.49x0.84x0.82x-110.52x-0.25x
Interest Paid0000000000
Taxes Paid0000000000

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Persistent operating cash burn

Net Income Unsupported by Operating Cash

Based on reported quarterly figures, LEGN posted $51.7M of net income in 2026Q3 yet generated negative operating cash flow of -$35.9M, an OCF-to-net-income ratio of -0.69 that signals earnings are not converting to cash.

The divergence between accounting profit and operating cash flow suggests the positive quarterly net income is driven by non-cash or partnership-related items rather than collections from patients and partners. Over the last ten quarters, operating cash flow was negative in most periods, which may indicate that reported profitability has limited bearing on the company's actual cash generation. Investors should monitor whether working capital build and milestone timing explain this gap, as the current evidence does not establish a sustainable conversion pathway.

Free Cash Flow Remains Deeply Negative

As reported in financial statements, LEGN's free cash flow margin reached -11.5% in 2026Q3 and was -36.5% in 2026Q1, with cumulative FCF negative across most of the observed ten quarters despite revenue expansion.

Free cash flow has been negative in the majority of recent quarters, with the deepest burn of -$126.6M occurring in 2025Q4 and an intermittent positive print in 2025Q3 that appears to be timing-driven rather than structural. The pattern suggests revenue growth of the Carvykti franchise has not yet translated into self-funding economics. Investors should watch whether FCF margins can move sustainably toward breakeven rather than relying on single-quarter inflections.

Working Capital Swings Dominate Cash Profile

According to reported cash flow statements, working capital changes of -$94.2M in 2026Q3 and -$100.5M in 2026Q2 consumed far more cash than the company's reported depreciation and amortization, indicating receivable or inventory dynamics are a primary cash driver.

The magnitude of working capital outflows relative to D&A suggests collections timing and manufacturing inventory build are material to quarterly cash results. Such swings may reflect milestone receivables or partner settlement timing rather than deteriorating customer demand, though the reported data does not isolate the components. Warrants further investigation into receivable aging and partner reimbursement cadence before drawing firm conclusions about working capital efficiency.

Light Capital Intensity Amid Scaling Needs

Based on reported figures, LEGN's capital expenditure ran at just 1.6% of revenue in 2026Q3 and 8.5% in 2026Q1, a low and volatile intensity that may understate future manufacturing investment requirements.

Capex has been modest relative to revenue, with a peak of $26.0M in 2026Q1, which may reflect reliance on partner-funded or leased manufacturing capacity rather than owned infrastructure. Low capital intensity preserves near-term cash but could mask capacity constraints that require investment as patient volumes scale. Investors should monitor whether capex steps up meaningfully to support additional treatment slots.

Stock Compensation Masks Cash Reality

As reported in financial statements, stock-based compensation was $17.3M in 2026Q2 and $15.0M in 2025Q3, amounts that flatter operating cash metrics relative to a company funding payroll with equity rather than cash.

Stock-based compensation is excluded from operating cash burn in the reported cash flow framework, so the true economic cost of talent retention is higher than the cash figures alone suggest. The absence of dividends and buybacks in the reported periods means the company has no distributions to offset, but also no demonstrated internal funding of growth. Analysts should treat the reported free cash flow as an incomplete picture of economic burn and monitor dilution alongside cash metrics.

LEGN — Frequently Asked Questions

Quick answers to the most common questions about buying LEGN stock.

How much cash does Legend Biotech Corporation (LEGN) generate from operations?

Legend Biotech Corporation (LEGN) generated $-100.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Legend Biotech Corporation's free cash flow?

Legend Biotech Corporation (LEGN) reported negative free cash flow of $168.0M in 2025, indicating capital requirements exceeded cash from operations.

What is Legend Biotech Corporation's capital expenditure (CapEx)?

Legend Biotech Corporation (LEGN) spent $67.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.